search
Back to results

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Primary Purpose

Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
anti-thymocyte globulin
busulfan
cyclophosphamide
cyclosporine
etoposide
filgrastim
methotrexate
allogeneic hematopoietic stem cell transplantation
Sponsored by
Fairview University Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chediak-Higashi Syndrome focused on measuring Chediak-Higashi syndrome, X-linked lymphoproliferative syndrome, disease-related problem/condition, familial erythrophagocytic lymphohistiocytosis, genetic diseases and dysmorphic syndromes, graft versus host disease, hematologic disorders, hemophagocytic lymphohistiocytosis, histiocytosis, immunologic disorders and infectious disorders, primary immunodeficiency disease, rare disease, virus-associated hemophagocytic syndrome

Eligibility Criteria

0 Years - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Patients diagnosed with any of the following active but stable, or nonactive/quiescent, hemophagocytic disorders: Hemophagocytic lymphohistiocytosis (HLH) Fever greater than 38.5 degrees Celsius Splenomegaly (greater than 3 cm below costal margin) Hemophagocytosis in bone marrow or spleen or lymph nodes Disease may be confirmed by positive family history No evidence of malignancy Hypertriglyceridemia and/or hypofibrinogenemia Fasting triglycerides at least 2.0 mmol/L or at least 3 standard deviations above normal for age Fibrinogen no greater than 1.5 g/L or no greater than 3 standard deviations above normal Cytopenia (affecting at least 2 of 3 lineages in the peripheral blood) Hemoglobin less than 9.0 g/L Platelet count less than 100,000/mm3 X-linked lymphoproliferative disorder (XLP) Two or more maternally related males manifesting at least one of the following XLP phenotypes: Fulminant infectious mononucleosis Dysgammaglobulinemia Malignant lymphoma/lymphoproliferative disorder Aplastic anemia Lymphoid granulomatosis/vasculitis OR A maternally related male in an established XLP kindred who has strong genetic (RFLP) linkage to the XLP locus Chediak-Higashi syndrome Partial oculocutaneous albinism (hair, skin, eyes) Frequent bacterial infections Large peroxidase positive granules in leukocytes of peripheral blood or bone marrow Positive family history or parental consanguinity is supportive of the diagnosis May not have entered accelerated phase as defined by any of the following: Lymphadenopathy Pancytopenia Histiocytes with hemophagocytosis in bone marrow, lymph nodes, liver, or spleen Viral associated hemophagocytic syndrome (VAHS) Relapsed after prior therapy or supportive care Diagnostic criteria as for HLH No hemophagocytic disorders secondary to underlying malignancy Patients 35 years of age and under must have a hematopoietic stem cell donor that is one of the following: HLA A and B identical OR Single HLA A or B serologic mismatch with DRB1 identity OR HLA A or B serologic identity with a single DRB1 mismatch Patients 36 to 55 years of age must have a hematopoietic stem cell donor that is one of the following: HLA A and B and HLA DRB1 identical OR Single HLA A or B serologic mismatch with DRB1 identity Patients receiving umbilical cord blood must have an unrelated donor with no more than two antigen HLA A, B, or DRB1 mismatches --Patient Characteristics-- Performance status: Karnofsky 70-100% OR Age less than 16 years: Lansky 50-100% Life expectancy: Not severly limited by another disease Hepatic: SGOT less than 3 times normal Bilirubin less than 2.5 mg/dL Renal: Creatinine normal OR Creatinine clearance or glomerular filtration rate greater than 50% normal Cardiovascular: If symptomatic, ventricular ejection fraction must be greater than 40% and must improve with exercise OR Shortening fraction normal on echocardiogram Pulmonary: If symptomatic, DLCO greater than 45% predicted (corrected for hemoglobin) In children unable to perform pulmonary function testing, oxygen saturation must be greater than 95% Other: HIV negative No significant active infections

Sites / Locations

  • Fairview University Medical Center

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
July 5, 2000
Last Updated
June 23, 2005
Sponsor
Fairview University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00006056
Brief Title
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
October 2003
Overall Recruitment Status
Unknown status
Study Start Date
March 2000 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Fairview University Medical Center

4. Oversight

5. Study Description

Brief Summary
OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders. II. Determine the rate of disease free survival, incidence of graft failure, and incidence of graft versus host disease in these patients after undergoing this treatment regimen.
Detailed Description
PROTOCOL OUTLINE: Patients receive oral busulfan twice a day on days -9 to -6; cyclophosphamide IV over 1 hour on days -5 to -2; etoposide IV over 4 hours on days -5 to -3; and anti-thymocyte globulin IV twice a day on days -2 and -1 and days 1 and 2. Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Filgrastim (G-CSF) is administered subcutaneously beginning on day 1 and continuing until blood counts recover. Patients receive graft versus host disease prophylaxis with methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1-4 hours (orally once the patients resumes eating) every 12 hours (every 8 hours for pediatric patients) starting on or prior to day -3 and continuing up to 1 year. Patients are followed at days 28 and 100, at 6 months and 1 year, and then annually for 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
Keywords
Chediak-Higashi syndrome, X-linked lymphoproliferative syndrome, disease-related problem/condition, familial erythrophagocytic lymphohistiocytosis, genetic diseases and dysmorphic syndromes, graft versus host disease, hematologic disorders, hemophagocytic lymphohistiocytosis, histiocytosis, immunologic disorders and infectious disorders, primary immunodeficiency disease, rare disease, virus-associated hemophagocytic syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Enrollment
40 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
anti-thymocyte globulin
Intervention Type
Drug
Intervention Name(s)
busulfan
Intervention Type
Drug
Intervention Name(s)
cyclophosphamide
Intervention Type
Drug
Intervention Name(s)
cyclosporine
Intervention Type
Drug
Intervention Name(s)
etoposide
Intervention Type
Drug
Intervention Name(s)
filgrastim
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Type
Procedure
Intervention Name(s)
allogeneic hematopoietic stem cell transplantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
0 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Patients diagnosed with any of the following active but stable, or nonactive/quiescent, hemophagocytic disorders: Hemophagocytic lymphohistiocytosis (HLH) Fever greater than 38.5 degrees Celsius Splenomegaly (greater than 3 cm below costal margin) Hemophagocytosis in bone marrow or spleen or lymph nodes Disease may be confirmed by positive family history No evidence of malignancy Hypertriglyceridemia and/or hypofibrinogenemia Fasting triglycerides at least 2.0 mmol/L or at least 3 standard deviations above normal for age Fibrinogen no greater than 1.5 g/L or no greater than 3 standard deviations above normal Cytopenia (affecting at least 2 of 3 lineages in the peripheral blood) Hemoglobin less than 9.0 g/L Platelet count less than 100,000/mm3 X-linked lymphoproliferative disorder (XLP) Two or more maternally related males manifesting at least one of the following XLP phenotypes: Fulminant infectious mononucleosis Dysgammaglobulinemia Malignant lymphoma/lymphoproliferative disorder Aplastic anemia Lymphoid granulomatosis/vasculitis OR A maternally related male in an established XLP kindred who has strong genetic (RFLP) linkage to the XLP locus Chediak-Higashi syndrome Partial oculocutaneous albinism (hair, skin, eyes) Frequent bacterial infections Large peroxidase positive granules in leukocytes of peripheral blood or bone marrow Positive family history or parental consanguinity is supportive of the diagnosis May not have entered accelerated phase as defined by any of the following: Lymphadenopathy Pancytopenia Histiocytes with hemophagocytosis in bone marrow, lymph nodes, liver, or spleen Viral associated hemophagocytic syndrome (VAHS) Relapsed after prior therapy or supportive care Diagnostic criteria as for HLH No hemophagocytic disorders secondary to underlying malignancy Patients 35 years of age and under must have a hematopoietic stem cell donor that is one of the following: HLA A and B identical OR Single HLA A or B serologic mismatch with DRB1 identity OR HLA A or B serologic identity with a single DRB1 mismatch Patients 36 to 55 years of age must have a hematopoietic stem cell donor that is one of the following: HLA A and B and HLA DRB1 identical OR Single HLA A or B serologic mismatch with DRB1 identity Patients receiving umbilical cord blood must have an unrelated donor with no more than two antigen HLA A, B, or DRB1 mismatches --Patient Characteristics-- Performance status: Karnofsky 70-100% OR Age less than 16 years: Lansky 50-100% Life expectancy: Not severly limited by another disease Hepatic: SGOT less than 3 times normal Bilirubin less than 2.5 mg/dL Renal: Creatinine normal OR Creatinine clearance or glomerular filtration rate greater than 50% normal Cardiovascular: If symptomatic, ventricular ejection fraction must be greater than 40% and must improve with exercise OR Shortening fraction normal on echocardiogram Pulmonary: If symptomatic, DLCO greater than 45% predicted (corrected for hemoglobin) In children unable to perform pulmonary function testing, oxygen saturation must be greater than 95% Other: HIV negative No significant active infections
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
K. Scott Baker
Organizational Affiliation
Fairview University Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Fairview University Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

We'll reach out to this number within 24 hrs